PALI - Palisade Bio, Inc. Stock Price, Fair Value and News

6.36USD-0.10 (-1.55%)Delayed

Market Summary

USD6.36-0.10

Delayed

-1.55%

PALI Stock Price

View Fullscreen

PALI RSI Chart

PALI Valuation

Market Cap

6.0M

Price/Earnings (Trailing)

-0.44

Price/Sales (Trailing)

10.84

Price/Free Cashflow

-0.55

PALI Price/Sales (Trailing)

PALI Profitability

Return on Equity

-134.01%

Return on Assets

-106.6%

Free Cashflow Yield

-180.97%

PALI Fundamentals

PALI Revenue

Revenue (TTM)

550.0K

Rev. Growth (Yr)

-100%

PALI Earnings

Earnings (TTM)

-13.5M

Earnings Growth (Yr)

-50.73%

Earnings Growth (Qtr)

-18.71%

Breaking Down PALI Revenue

Last 7 days

-5.2%

Last 30 days

-3.6%

Last 90 days

-1.4%

Trailing 12 Months

-73.0%

How does PALI drawdown profile look like?

PALI Financial Health

Current Ratio

4.87

PALI Investor Care

Shares Dilution (1Y)

110.00%

Diluted EPS (TTM)

-23.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	228.1K	335.4K	442.7K	550.0K
2022	0	0	0	120.8K
2020	18.9K	13.5K	13.5K	13.5K
2019	198.8K	137.7K	76.5K	15.4K
2018	260.0K	260.0K	260.0K	260.0K
2017	16.2K	16.2K	16.2K	260.0K
2016	10.0K	10.0K	10.0K	16.2K
2015	17.6K	15.1K	12.6K	10.4K
2014	11.7K	14.2K	16.7K	18.8K
2013	354.0K	278.3K	110.0K	110.0K
2012	394.9K	399.2K	403.4K	407.7K
2011	0	0	562.0K	390.6K
2010	0	0	0	733.4K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Palisade Bio, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 06, 2024	finley john david	sold (taxes)	-1,082	8.46	-128	ceo, cfo, director
May 06, 2024	jones mitchell lawrence	acquired	-	-	460	ceo, cfo, director
May 06, 2024	jones mitchell lawrence	sold (taxes)	-1,159	8.46	-137	ceo, cfo, director
May 06, 2024	finley john david	acquired	-	-	443	ceo, cfo, director
Mar 11, 2024	finley john david	acquired	-	-	5,558	ceo, cfo, director
Feb 09, 2024	neal james r	acquired	-	-	10,920	-
Feb 08, 2024	trenschel robert j.	acquired	-	-	10,920	-
Feb 08, 2024	csimma cristina	acquired	-	-	12,800	-
Feb 08, 2024	diaz stephanie	acquired	-	-	12,800	-
Feb 06, 2024	jones mitchell lawrence	sold (taxes)	-938	0.4361	-2,153	chief medical officer

Which funds bought or sold PALI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-4,288	8,965	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-403	841	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	1,198	1,198	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	new	-	287,352	287,352	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	added	43.54	-337	11,258	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	7,264	7,264	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	sold off	-100	-1.00	-	-%
May 13, 2024	HRT FINANCIAL LP	new	-	12,000	12,000	-%
May 13, 2024	FMR LLC	reduced	-92.11	-21.00	1.00	-%
May 13, 2024	UBS Group AG	reduced	-11.71	-600	887	-%

Are Funds Buying or Selling PALI?

Are funds buying PALI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PALI

No. of Funds

Unveiling Palisade Bio, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	486,914	SC 13G/A
Feb 13, 2024	lind global fund ii lp	1.7%	158,355	SC 13G/A
Feb 09, 2024	l1 capital global opportunities master fund, ltd.	0%	0	SC 13G/A
Feb 06, 2024	intracoastal capital, llc	1.9%	180,532	SC 13G/A
Sep 15, 2023	lind global fund ii lp	7.9%	743,313	SC 13G
Sep 15, 2023	l1 capital global opportunities master fund, ltd.	6.4%	584,958	SC 13G
Feb 14, 2023	altium capital management lp	0%	0	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	281,054	SC 13G
Feb 13, 2023	lind global fund ii lp	1.4%	30,987	SC 13G/A
Feb 08, 2023	intracoastal capital, llc	5.7%	131,086	SC 13G/A

Recent SEC filings of Palisade Bio, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	424B3	Prospectus Filed
May 16, 2024	3	Insider Trading
May 13, 2024	10-Q	Quarterly Report
May 10, 2024	8-K	Current Report
May 10, 2024	D	D
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 08, 2024	S-3	S-3
May 03, 2024	8-K	Current Report
Apr 10, 2024	8-K	Current Report

Peers (Alternatives to Palisade Bio, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Palisade Bio, Inc. News

Latest updates

Palisade Bio, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2
Revenue	-	-	-	300	-	250	126	3.00	3.00	3.00	6.00	3.00	3.00	8.00	5.00	3.00	3.00	253	253	253	3.00	3.00
Operating Expenses	16.5%	3,673	3,154	3,778	3,609	2,779	3,848	3,444	1,816	1,841	1,996	2,135	2,127	1,926	2,459	1,807	2,085	2,275	-	-	-	-
S&GA Expenses	-100.0%	-	1,558	1,674	1,432	1,538	1,505	2,382	1,404	1,191	1,300	1,368	1,301	972	945	928	1,188	1,261	1,182	-	-	-
R&D Expenses	-	-	-	-	-	-	-	410	466	446	697	767	825	954	1,514	879	897	1,015	1,169	1,225	1,384	2,585
Interest Expenses	-75.0%	1.00	4.00	8.00	3.00	-	3.00	-	28.00	11.00	3.00	4.00	2.00	507*	2.00	4.00	1.00	-	-	-	-	-
Net Income	-18.7%	-3,527	-2,971	-3,596	-3,393	-2,340	-3,720	-4,244	-1,843	-1,851	-2,384	-2,037	-1,763	-1,436	-3,113	-320	-1,830	-627	-	-	-	-
Net Income Margin	-9.7%	-24.52*	-22.36*	-29.48*	-40.08*	-54.34*	-118.03*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-15.8%	-3,180	-2,746	-2,662	-2,209	-3,536	-3,316	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.0%	12,652	14,052	17,067	18,290	15,262	15,763	16,266	7,806	8,350	12,512	16,274	14,949	8,915	3,019	15,170	17,102	11,361	6,584	8,944	3,522	5,406
Current Assets	-9.9%	12,013	13,328	16,266	17,411	14,309	14,733	15,158	7,415	8,258	11,506	16,092	14,725	8,756	896	14,991	16,242	10,464	5,647	7,966	2,708	4,538
Cash Equivalents	-9.1%	11,300	12,432	15,312	16,403	13,297	12,383	13,985	4,980	6,644	10,495	14,104	12,653	615	713	751	1,519	10,030	5,115	7,300	2,281	4,005
Net PPE	-50.0%	5.00	10.00	10.00	11.00	9.00	10.00	12.00	2.00	2.00	3.00	3.00	3.00	7.00	5.00	15.00	22.00	31.00	41.00	52.00	63.00	76.00
Liabilities	-5.5%	2,588	2,739	2,985	2,490	1,515	3,284	3,836	3,595	3,558	5,147	12,354	24,393	1,186	10,118	1,047	867	1,383	1,458	1,901	1,559	2,134
Current Liabilities	-4.6%	2,467	2,586	2,649	2,335	1,315	3,012	3,513	2,860	1,864	2,496	2,920	3,850	1,015	8,082	1,002	676	1,186	1,225	1,581	1,071	1,210
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	94.00	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	94.00	-	-	-	-	-	-	-
Shareholder's Equity	-11.0%	10,064	11,313	14,082	15,800	13,747	12,479	12,430	4,211	4,792	7,365	3,920	-	7,729	9,768	14,122	16,234	9,978	5,126	7,043	1,963	3,272
Retained Earnings	-202.9%	-125,000	121,500	-	-	-	-	-	-	-	-	-95,715	-103,800	-240,527	-68,026	-233,823	-231,501	-229,550	-221,975	-219,937	-218,174	-216,737
Additional Paid-In Capital	1.8%	135,087	132,724	132,523	130,652	125,229	121,637	116,839	105,180	103,454	102,002	99,503	94,242	248,228	51,396	247,775	247,568	239,440	227,067	226,958	220,125	219,993
Shares Outstanding	37.8%	851	618	614	457	304	196	38.00	24.00	22.00	19.00	11.00	15.00	4.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	11,600	-	-	-	8,100	-	-	-	39,200	-	-	-	12,444	-	-	-	4,578	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-15.8%	-3,180	-2,746	-2,662	-2,199	-3,526	-3,306	-3,040	-3,250	-3,764	-3,055	-2,746	-7,722	-1,250	-1,548	-869	-673	-1,677	-2,048	-1,897	-1,643	-1,665
Share Based Compensation	-36.2%	118	185	202	144	93.00	86.00	252	336	358	683	144	495	569	470	664	804	76.00	119	295	129	338
Cashflow From Investing	-	-	-	-	-	-	-10.00	-	-	-	-	-348	-	-	-1.00	1.00	-	-	-	-	-	-
Cashflow From Financing	1610.4%	2,024	-134	1,571	5,309	4,440	1,714	12,045	1,586	-87.00	-554	4,545	19,466	1,152	1,511	100	-6,314	6,593	-136	6,922	-78.85	-117

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PALI Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Operating expenses:

License revenue

$ 0

$ 250

Research and development

2,214

1,241

General and administrative

1,459

1,538

Total operating expenses

3,673

2,779

Loss from operations

(3,673)

(2,529)

Other (expense) income:

Interest expense

(1)

Other income

147

189

Total other income, net

146

189

Net loss

$ (3,527)

$ (2,340)

(Loss) income per common share:

Basic net loss per common share

^[1]

$ (4.59)

$ (8.13)

Diluted net loss per common share

^[1]

$ (4.59)

$ (8.13)

Weighted average shares used in computing (loss) income per common share:

Basic weighted average shares used in computing net loss per common share

^[1]

768,137

287,702

Diluted weighted average shares used in computing net loss per common share

^[1]

768,137

287,702

[1]	(*) Basic and diluted loss per common share and basic and diluted weighted average share used in computing basic and diluted loss per common share for the three months ended March 31, 2023 has been adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.

PALI Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 11,276,000	$ 12,432,000
Prepaid expenses and other current assets	737,000	896,000
Total current assets	12,013,000	13,328,000
Restricted cash	26,000	26,000
Property and equipment, net	5,000	10,000
Operating lease right-of-use asset	170,000	198,000
Other noncurrent assets	438,000	490,000
Total assets	12,652,000	14,052,000
Current liabilities:
Accounts payable	459,000	698,000
Accrued liabilities	1,670,000	831,000
Accrued compensation and benefits	213,000	778,000
Current portion of operating lease liability	125,000	121,000
Insurance financing debt	0	158,000
Total current liabilities	2,467,000	2,586,000
Warrant liability	2,000	2,000
Contingent consideration obligation	61,000	61,000
Operating lease liability, net of current portion	58,000	90,000
Total liabilities	2,588,000	2,739,000
Commitments and contingencies (Note 8)
Stockholders' equity:
Common stock, $0.01 par value; 280,000,000 shares authorized; 851,340 and 618,056 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	8,000	6,000
Additional paid-in capital	135,087,000	132,811,000
Accumulated deficit	(125,033,000)	(121,506,000)
Total stockholders' equity	10,064,000	11,313,000
Total liabilities and stockholders' equity	12,652,000	14,052,000
Series A Preferred Stock [Member]
Stockholders' equity:
Series A Convertible Preferred Stock, $0.01 par value, 7,000,000 shares authorized; 200,000 issued and outstanding at March 31, 2024 and December 31, 2023	$ 2,000	$ 2,000

About Palisade Bio, Inc.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.

CEO	Mr. J. D. Finley
WEBSITE	palisadebio.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Palisade Bio, Inc. Frequently Asked Questions

What is the ticker symbol for Palisade Bio, Inc.? What does PALI stand for in stocks?

PALI is the stock ticker symbol of Palisade Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Palisade Bio, Inc. (PALI)?

As of Fri May 17 2024, market cap of Palisade Bio, Inc. is 5.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PALI stock?

You can check PALI's fair value in chart for subscribers.

What is the fair value of PALI stock?

You can check PALI's fair value in chart for subscribers. The fair value of Palisade Bio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Palisade Bio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PALI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Palisade Bio, Inc. a good stock to buy?

The fair value guage provides a quick view whether PALI is over valued or under valued. Whether Palisade Bio, Inc. is cheap or expensive depends on the assumptions which impact Palisade Bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PALI.

What is Palisade Bio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PALI's PE ratio (Price to Earnings) is -0.44 and Price to Sales (PS) ratio is 10.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PALI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Palisade Bio, Inc.'s stock?

In the past 10 years, Palisade Bio, Inc. has provided -0.739 (multiply by 100 for percentage) rate of return.